CN Patent

CN114984191B — 一种多肽类药物口服递送组合物

Assigned to Jilin Huisheng Biopharmaceutical Co ltd · Expires 2022-10-25 · 4y expired

What this patent protects

本发明涉及一种适用于多肽类药物口服递送的药物组合物，所述药物组合物的组成成分包括第一类型颗粒和第二类型颗粒；所述第一类型颗粒包含280‑300 mg的SNAC和5‑20%的GLP‑1受体激动剂，所述第二类型颗粒包含5‑20 mg的SNAC和80‑95%的GLP‑1受体激动剂。本发明的口服递送药物组合物能够更加有效的口服递送GLP‑1衍生物或GLP‑1相关的多靶点激动剂，具备优异的口服生物利用度，应用前景广阔。

USPTO Abstract

本发明涉及一种适用于多肽类药物口服递送的药物组合物，所述药物组合物的组成成分包括第一类型颗粒和第二类型颗粒；所述第一类型颗粒包含280‑300 mg的SNAC和5‑20%的GLP‑1受体激动剂，所述第二类型颗粒包含5‑20 mg的SNAC和80‑95%的GLP‑1受体激动剂。本发明的口服递送药物组合物能够更加有效的口服递送GLP‑1衍生物或GLP‑1相关的多靶点激动剂，具备优异的口服生物利用度，应用前景广阔。

Drugs covered by this patent

Patent Metadata

Patent number
CN114984191B
Jurisdiction
CN
Classification
—
Expires
2022-10-25
Drug substance claim
No
Drug product claim
No
Assignee
Jilin Huisheng Biopharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.